Actively Recruiting
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-10-31
40
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
CONDITIONS
Official Title
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have histologically or cytologically confirmed non-small cell lung cancer.
- Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
- ECOG PS 0-2
- Adequate organ and bone marrow function.
You will not qualify if you...
- History of previous radiotherapy.
- Previous immune-related pneumonitis grade 2 or higher.
- Local lesions requiring surgery.
- History of another primary malignancy.
- History of active primary immunodeficiency.
- Mixed small cell lung cancer and non-small cell lung cancer histology.
- Any unresolved toxicity during pre-study chemoradiotherapy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
L
Lei Deng, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here